NEW HAVEN, Conn., Jan. 13, 2016 /PRNewswire/ -- LCS Group, LLC announced today that it is accelerating commercialization efforts of its exclusively licensed U.S. Patent Number 8,318,813 and U.S. Patent Application No. 14/464,249, both titled "Method of Treating Binge Eating Disorder" ("BED") and which encompass claims for the treatment of BED with Shire's Vyvanse®, the former invalidated by the U.S. Patent Trial & Appeal Board on June 4, 2015 based on an Inter Partes Review (IPR) initiated by Shire Development LLC. The accelerated commercialization phase is based on the invalidated '813 Patent's owner, Lucerne Biosciences, LLC, making available to the global public its deception detection technology through a January 11, 2016 press release (hyperlink below). The deception detection technology, developed by Lucerne Biosciences during and after the Shire-initiated IPR, has been packaged for the general public as a "sourcing investigation" designed to help any reasonable person reading it "detect deception," including "highly coordinated deception" across multiple parties. The technology uses composite profiling techniques with recursive framing to amplify what may seem on first glace as nothing significant or just a random series of events.
CEO of LCS Group, LLC, Louis Sanfilippo, stated, "Lucerne Biosciences' deception detection package is a great opportunity for the public-at-large to see how deception works, at its subtlest representational features, with some of the best teachings coming from US intelligence agencies, like a deception detection expert formerly with the Central Intelligence Agency. Read Lucerne's sourcing investigation and you may just see the world differently. It's loaded with examples, more than you can count, based on an extraordinary real-life story that goes far beyond Shire's relentless IPR proceeding that ended in the '813 Patent's invalidation. You can investigate further if you're interested in honing your 'deception detection skills.' By the end of it, you can become your own bona-fide 'deception detection expert' without even having to pay for a course." Sanfilippo added, "The 'deception detection technology' is a critical feature of a collaboration LCS Group entered into with Lucerne Biosciences, as well as other parties, on October 1, 2014 after Shire failed to show any interest in the truth of the matter despite being discreetly informed that it had more than a few small problems with its IPR petition. Now that the package is broadly available to the general public, all involved parties are ready to advance a multi-pronged platform aimed at 'publicly getting at the truth' behind Shire's IPR."
Shire's IPR petition was initially filed against LCS Group on May 9, 2014. Subsequently, the '813 Patent was acquired by Lucerne Biosciences and then exclusively licensed to LCS Group to handle its commercialization while Lucerne Biosciences handled the sourcing investigation and legal-related activities according to the terms of the Exclusive License between the two companies.
About LCS Group, LLC
LCS Group is a privately-held intellectual property development and commercialization company focused on novel therapies to help people suffering from psychiatric disorders and other behavioral health problems.
The Patent '813 Story, Part II, Version 2 (updated January 13, 2016) at: http://www.4shared.com/download/p6Z7aQygce/updated_1132016_-__The_Patent_.pdf?sbsr=1aff6bfee92697c807b8e8bfbc24230b961&lgfp=3000
Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology (June 11, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-begins-accelerated-multi-party-public-expansion-phase-of-its-counter-intelligence-technology-300202785.html
PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate (June 13, 2015) at: http://www.prnewswire.com/news-releases/ptab-invalidates-lucerne-biosciences-813-patent-for-the-treatment-of-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300098752.html
Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate (March 6, 2015) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-announces-publication-of-claimed-methods-for-treating-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300046271.html
LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder (May 13, 2015) at: http://www.prnewswire.com/news-releases/lcs-group-announces-exclusive-license-from-lucerne-biosciences-to-commercialize-813-patent-and-249-application-through-shires-marketing-of-lisdexamfetamine-dimesylate-for-binge-eating-disorder-300083124.html
LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder (December 26, 2014) at: http://www.prnewswire.com/news-releases/lcs-therapeutics-and-lucerne-biosciences-to-commercialize-813-patent-for-lisdexamfetamine-dimesylate-in-the-treatment-of-binge-eating-disorder-300013986.html
Louis Sanfilippo, MD
CEO, LCS Group, LLC
SOURCE LCS Group, LLC